CASMED Places 900th FORE-SIGHT® Cerebral Oximeter
Milestone Accelerated with Introduction of Next-Generation FORE-SIGHT ELITE™
Branford, Conn. (December 3, 2013) – CAS Medical Systems, Inc. (NASDAQ: CASM), (CASMED), a leader in medical devices for non-invasive patient monitoring, today announced that the worldwide installed base of its FORE-SIGHT Cerebral Oximeters surpassed 900 in November. The installed base includes seven of the top 20 adult cardiac surgery centers and three of the top ten pediatric centers in the U.S. The Company had previously disclosed an installed base of 845 units as of September 30, 2013.
"The growth of FORE-SIGHT placements reflects the quality of our products and support service, as well as an increasing recognition of the importance of cerebral monitoring during and after surgery," said Thomas M. Patton, President and Chief Executive Officer of CASMED. "With the introduction of the FORE-SIGHT ELITE in September, we are seeing an acceleration in order volume, including a significant number of new accounts. Of the early ELITE placements in new accounts, approximately one-third was to hospitals and departments where cerebral oximetry is being adopted for the first time, and the other two thirds were previously served by competitors."
Mr. Patton added, "In July the National Society of Perfusionists, representing clinicians that operate heart/lung machines, issued new standards recommending that cerebral monitoring occur on all by-pass procedures. This represents the first clinical society to recommend cerebral oximetry monitoring for a class of surgical patients, and the endorsement is a significant step forward for the industry."
The FORE-SIGHT ELITE is lighter and more portable than the prior model and includes several important new features for customers, such as the ability to monitor four channels of patient information; a larger, higher contrast viewing screen; and intuitive touch-screen controls. A revolutionary system using five wavelengths of light to interrogate tissue under the sensor allows the ELITE to measure oxygenation at levels of accuracy previously not seen.
About CASMED® - Monitoring What's Vital
CASMED is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company's FORE-SIGHT® Absolute Cerebral Oximeter provides a highly accurate, non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation. Direct monitoring of tissue oxygenation provides a superior and powerful tool to alert clinicians to otherwise unrecognized and dangerously low levels of oxygenation of the brain and other tissues, thereby allowing them to intervene appropriately in the care of their patients. In addition to FORE-SIGHT Oximeters and accessories, the Company provides a line of bedside patient vital signs monitoring products, proprietary non-invasive blood pressure monitoring solutions for OEM use, neonatal intensive care supplies, and service. CASMED products are designed to provide unique monitoring solutions that are vital to patient care. For more information regarding CASMED, visit the Company's website at www.casmed.com.
Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, the impact of any product liability or other adverse litigation, working capital and availability of capital, commercialization and technological difficulties, the impact of actions and events involving key customers, vendors, lenders, competitors, and other risks detailed in the Companys Form 10-K for the year ended December 31, 2012, and other subsequent Securities and Exchange Commission filings.
Such statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release, the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will", and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forwardlooking statements, whether as a result of future events, new information, or otherwise.
CAS Medical Systems, Inc.
Jeffery A. Baird
Chief Financial Officer
Don Markley (email@example.com)
Bruce Voss (firstname.lastname@example.org)